SCHEMBL327691

SCHEMBL327691

COC(C)C(=O)N1CCC(=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.40
HPGD P15428 3/20 0.39
LMNA P02545 2/20 0.37
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
RORC P51449 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 1/20 0.33
ALOX12 P18054 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PTGS2 P35354 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13359380 0.83 HPGD (0.41) HPGDLMNAALDH1A1SMN1; SMN2ALOX15
SCHEMBL15502872 0.83 HPGD (0.41) HPGDLMNAALDH1A1SMN1; SMN2ALOX15
SCHEMBL10310589 0.80 LIPE (0.40) LIPEHPGDLMNAALDH1A1SMN1; SMN2
SCHEMBL640493 0.79 LIPE (0.44) LIPELMNAALDH1A1SMN1; SMN2HTT
SCHEMBL14159619 0.79 SMN1; SMN2 (0.43) HPGDLMNAALDH1A1SMN1; SMN2ALOX15
SCHEMBL12539736 0.79 DPP4 (0.40) HPGDLMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL18288694 0.79 LMNA (0.38) LIPEHPGDLMNAALDH1A1SMN1; SMN2
SCHEMBL15451943 0.76 CYP1A2 (0.46) HPGDALDH1A1HSD17B10MAPTKDM4E
SCHEMBL11401289 0.76 ALDH1A1 (0.55) LIPEHPGDLMNAALDH1A1SMN1; SMN2
SCHEMBL3548621 0.74 HPGD (0.36) HPGDLMNAALDH1A1SMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293869-B2 Polymer conjugates of GLP-1 NEKTAR THERAPEUTICS (US) 2012-10-23 US disclosed
US-20120244597-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2012-09-27 US disclosed
US-20120245289-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2012-09-27 US disclosed
US-8273339-B2 Polymer-based compositions and conjugates of antimicrobial agents NEKTAR THERAPEUTICS (US) 2012-09-25 US disclosed
US-8247536-B2 Factor VIII compositions NEKTAR THERAPEUTICS (US) 2012-08-21 US disclosed
US-20120195847-A1 POLYMER CONJUGATES OF BIPHALIN PEPTIDES NEKTAR THERAPEUTICS (US) 2012-08-02 US disclosed
US-20120178692-A1 DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2012-07-12 US disclosed
US-20120100096-A1 CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS NEKTAR THERAPEUTICS (US) 2012-04-26 US disclosed
US-8143378-B2 Polymer factor VIII moiety conjugates NEKTAR THERAPEUTICS (US) 2012-03-27 US disclosed
US-8133977-B2 Polymer-factor VIII moiety conjugates NEKTAR THERAPEUTICS (US) 2012-03-13 US disclosed
US-20100130428-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-27 US disclosed
US-20100125049-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-20 US disclosed
US-20100120982-A1 POLYMER-FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-13 US disclosed
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-13 US disclosed
US-7714114-B2 Conjugates of an EPO moiety and a polymer NEKTAR THERAPEUTICS (US) 2010-05-11 US disclosed
US-20100021481-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY NEKTAR THERAPEUTICS (US) 2010-01-28 US disclosed
US-20090280550-A1 Polymer-Factor IX Moiety Conjugates NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-11-12 US disclosed
US-7579444-B2 Polymer-factor IX moiety conjugates NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-08-25 US disclosed
US-20090041714-A1 Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-02-12 US disclosed
US-20080058504-A1 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor NEKTAR THERAPEUTICS 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090041714-A1 Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia F13B, F8, F13A1 LIPE 2032/4885HPGD 2385/4885LMNA 2605/4885
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES F8, F9, F13B LIPE 2104/4885HPGD 2095/4885LMNA 700/4885
US-20100120982-A1 POLYMER-FACTOR IX MOIETY CONJUGATES F9, F13A1, F13B LIPE 3576/4885HPGD 1151/4885LMNA 1157/4885
US-20100021481-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY TNF, TNFRSF1A, TNFRSF9 LIPE 3040/4885HPGD 419/4885LMNA 2141/4885
US-20100125049-A1 POLYMER FACTOR VIII MOIETY CONJUGATES F8, F9, F13B LIPE 2104/4885HPGD 2095/4885LMNA 700/4885
US-20120178692-A1 DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES F8, F9, F13B LIPE 2549/4885HPGD 1325/4885LMNA 965/4885
US-20120245289-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES F8, F9, F13B LIPE 2335/4885HPGD 1782/4885LMNA 811/4885
US-20080058504-A1 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor F8, F13A1, F13B LIPE 779/4885HPGD 1011/4885LMNA 1408/4885
US-20120195847-A1 POLYMER CONJUGATES OF BIPHALIN PEPTIDES NGLY1, DNPEP, CIAPIN1 LIPE 4487/4885HPGD 2459/4885LMNA 4562/4885
US-20100130428-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 LIPE 3566/4885HPGD 1255/4885LMNA 860/4885
US-20120100096-A1 CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS SLC19A1, FOLR1, SLC46A1 LIPE 4672/4885HPGD 3787/4885LMNA 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.